|
11 January 2010 ,
Written by Dhruv Tanwar
|
|
Data capture company DSG says its electronic data capture technology supports studies on early detection for Alzheimer’s, Parkinson’s and Diabetes. DSG, which deals in electronic data capture (EDC) technology, has partnered with a leading pharmaceutical technology company to speed up the early detection of Alzheimer’s, Parkinson’s, and Diabetes.
DSG Inc. supports clinical trial data collection and management with innovative technology solutions including electronic data capture with specialized clinical data management services, electronic patient diaries, clinical trial management systems and digital on-demand case report form publishing management software. The company says it has supported over 800 clinical trials for more than 325 companies at over 18,000 sites in over 68 countries. Founded in 1992, DSG is headquartered in Malvern, Pa., with additional offices in the US, Japan and India.
“We are delighted to provide this Pharma leader with the latest critical technology solutions, helping to reach an incredibly important goal – the early detection of debilitating diseases,” said Tony Varano, CEO, DSG, Inc. “What is especially gratifying is that DSG provides select solution modules specific to their needs, rather than the ‘cookie cutter’ approach to most clinical trial data collection solutions.”
In a statement, DSG said that the focus of this endeavor is on developing molecular imaging products that are leading the way to the early detection of human diseases. It said that its eCaseLink EDC supports three current clinical trials for Alzheimer’s disease, Parkinson’s disease and Diabetes, bu supplying real-time capability to review case documents and metrics across all study sites, significantly increasing clinical trial management speed, while reducing study management costs by as much as 30 percent. It also allows the pharmaceutical diagnostic and therapeutic company not only to collect and manage their data in real time, but it also gives them the option to add needed functionality as studies progress. |